Oculus Innovative Sciences, Inc. Announces Results From Study of Microcyn® Technology-Based Atrapro™ Antipruritic Hydrogel Used in Combination With Neosalus® Cream in Treatment of Atopic Dermatitis

Published: Oct 09, 2012

PETALUMA, Calif., Oct. 9, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced results of a multicenter, prospective and open-label pilot study in which Microcyn® Technology-based Atrapro™ Antipruritic Hydrogel was evaluated in combination with Neosalus® Cream in the treatment of atopic dermatitis. The two products are frequently marketed as a comprehensive treatment regimen for skin dermatoses including atopic dermatitis.

Back to news